Microcephaly is an important sign of neurological malformation and predictor of future disability.
microcephaly and appropriately managing its consequences remain important global public health priorities.
Introduction
This review was conducted in response to the recent outbreak of microcephaly associated with congenital Zika virus (ZIKV) infection, first identified in Latin America. Attention has been drawn to ZIKV because the previously unknown congenital syndrome was discovered in a susceptible population and can potentially affect a very large number of infants. ZIKV however is one of a group of infectious diseases that can be transmitted to the fetus and cause microcephaly and the microcephaly is likely to represent the tip of the iceberg in terms of developmental abnormalities, forming part of a syndrome for each infection.
Understanding the different causes of microcephaly will help clinicians, researchers, and hopefully policy makers contextualize the recent outbreak and can be applied to help the individual child, as well as to inform appropriate planning of services for the population.
In this article, we review the major congenital infections that can cause microcephaly, focusing on those with the largest disease burden and the strongest evidence for causation: cytomegalovirus (CMV), herpes simplex virus (HSV), rubella virus, Toxoplasma gondii (T. gondii), and ZIKV. We describe the epidemiology, pathogenesis, transmission, clinical features and long-term disability in childhood. Less frequent causes of primary microcephaly are not considered here. While congenital syphilis has a high disease burden in regions affected by ZIKV and varicella virus has recognised neurotropic properties, published reports describing primary microcephaly in the context of these two infections are scarce.
Microcephaly
Microcephaly is a clinical diagnosis made at or after birth that describes a small head. It does not necessarily mean abnormal brain development and some children with microcephaly are healthy. microcephaly is predominantly due to non-infectious causes, 11, 12 including genetic abnormalities, nutritional deficiencies, hypothyroidism, brain injury, alcohol, drugs, and placental insufficiency. 8, 9 A multi-centre retrospective analysis from Germany found that only 25 of 403 (6·2%) cases of microcephaly (for which a cause was identified) were due to maternal infections in pregnancy. 12 The prevalence of in utero or perinatal infections in cases of severe microcephaly is higher e.g. 46 of 284 (16%) cases in New York 2013-15. 13 A reduction in head size may be associated with intrauterine growth restriction, for example with CMV and ZIKV. This can be either symmetrically or asymmetrically reduced in size in relation to the overall anthropometry of the infant. The gestation at which an insult occurs, will determine when microcephaly is clinically detectable. An infection close to birth may result in brain damage but with a normal head circumference. Recent data suggest that microcephaly may be poorly sensitive for screening infants severely affected by congenital ZIKV infection, particularly as this consists of many other manifestations. 14 Clinically apparent, microcephaly is one of many fetal brain abnormalities that can lead to later neurodevelopmental sequelae. 15 Although a clinical diagnosis of microcephaly with normal brain imaging does not necessarily mean impaired brain growth, a reduction in skull volume is indicative of underlying cerebral cortical volume loss. 8, 16 A study of Finnish infants admitted to a neonatal ward for example, showed that a one standard deviation increase in head circumference at birth was associated with a 0·8-1·5 unit increase in cognitive scores at 56 months. 17 If we use microcephaly to screen for congenital diseases, and if OFC is normally distributed in the reference population, 2·3% of the population will be classified as having microcephaly, many of whom will be healthy. Conversely, many neonates with congenital infections that affect the brain will not have severe enough manifestations to cause microcephaly. To illustrate this, we simulate two scenarios ( Figure 1) . A definition of <-3 z-scores (0·1% of the population) 18, 19 is expected to be 99·9% specific, although much less sensitive (57%). 4 An assessment of 1501 cases of suspected microcephaly reported to the Brazilian notification system, showed that 21·7% of notified cases classified as 'definite or probable' had a normal head circumference (>-2 z-scores) and this cut-off had a sensitivity of 83% and specificity of 98%. 14 So although microcephaly is a good screening diagnosis for brain damage caused by a congenital infection, some cases will be normal and cases with neurological damage may not be identified. Further tools must therefore be employed.
Pathogenesis and embryology
The central nervous system becomes established from day 22 of embryonic development when the neural tube is formed. 20 The embryonic brain is initially composed entirely of proliferative neuronal progenitors which reside within the ventricular zone (VZ) bordering the neural tube lumen. However, with subsequent development, neurons begin to emerge and a new population of deeper subventricular zone (SVZ) neural progenitors arises. Proliferation of the SVZ cells contributes to further expansion of the brain's neuronal population. Proliferative VZ and SVZ neuronal progenitors persist until around mid-gestation, providing a target for pathogens via the cerebral blood supply which is now fully established. Experimental evidence shows that regulation of neural progenitor numbers and sub-types is vital for controlling brain size and morphology ( Figure 2 ). For example, mouse studies reveal that abnormal expansion of the VZ or SVZ neural progenitors increases brain size and produces macrocephaly. 21, 22 In contrast, a reduction in neural progenitor numbers due to cell death, cell cycle arrest or premature neuronal differentiation reduces brain size and produces microcephaly. [23] [24] [25] [26] The pathogenesis of CMV, HSV, rubella and ZIKV is described below. Little information is available on the mechanisms of congenital brain infection for T. gondii, where additional research is needed. The congenital infections we describe in this paper (summarised in Table 1) are responsible for a range of developmental brain defects, with the more severe cases occurring after infection during the first trimester of gestation, when the neural progenitors are actively multiplying and producing neurons (Figure 2 ). 43 ; CMV neural precursors 37 ). This research suggests that perturbation of neural progenitor populations may be the main cause of infection-related microcephaly.
CMV
CMV is capable of altering progenitor and neuronal fates through the downregulation of multipotency markers including Sox2 and Nestin. 44, 45 Neuronal differentiation has been found to be inhibited or delayed by CMV 37, 46, 47 or to occur prematurely after infection. 44 Recently, a new molecular mechanism downstream of CMV brain infection has emerged: PPARγ (peroxisome proliferator-activated receptor gamma) was found to increase following CMV infection of human neural stem cells and human fetal brain sections. Activation of PPARγ function alone was sufficient to impair neuronal differentiation, and a PPARγ inhibitor restored normal differentiation. Moreover, nuclear PPARγ was detected in the brains of congenitally infected fetuses. 47 These findings support a role for PPARγ in mediating congenital CMV brain disease.
HSV
HSV can infect multiple brain cell types (human 35, 38 , in vitro 42 and mouse 48 ) but how this leads to microcephaly is unclear. Infected organs including the brain, show tissue necrosis postmortem. 36 In vitro and animal studies suggest that HSV may initially induce an immune response that stimulates neural stem cell proliferation. Subsequently, brain infiltration by CD8(+) T cells limits proliferation through the stimulation of interferon-gamma. 49 Operation of a similar immune-mediated mechanism following congenital brain infection leading to microcephaly is possible but remains to be verified.
Rubella
The mechanisms by which rubella virus induces microcephaly remain largely unknown. 40, 41 and neurospheres 43 ). The exposure of these 3D cell cultures to the virus mimics many features of microcephaly in humans, including a decrease in neuronal production, reduced VZ thickness and overall smaller organoids. 40, 41, 53 This reduction in growth seems to result from cell cycle arrest 54 and/or an increase in cell death, 41, 43, 53, 54 and could indeed explain the microcephaly phenotype observed in ZIKV-infected human fetuses. Entry of ZIKV into neural progenitors has been suggested to occur via viral receptor AXL, which mediates ZIKV and dengue virus entry into human skin cells, 55 and is strongly expressed in VZ and SVZ neural progenitors. 56, 57 However, a recent study using human brain organoids revealed that genetic ablation of AXL alone is unable to prevent ZIKV infection, suggesting that other cell adhesion or entry factors may be involved. 58 Human fetal organotypic slice culture studies reveal that phospho-TANK Binding Kinase 1 (pTKB1),
relocates from centrosomes to mitochondria following ZIKV infection producing mitotic defects and supernumerary centrosomes that may exacerbate cell death. 57, 59 Injection of ZIKV into pregnant macaques and mice, or into the mouse brain, has recently confirmed some of the observations from human in vitro culture systems. [60] [61] [62] Dang and colleagues also discovered that ZIKV infection activates TLR3 (involved in activation of an immune response) and that TLR3 inhibition can attenuate apoptosis and decrease growth induced by viral infection. 40 The comparison of transcriptome profiles derived from infected and non-infected animal tissue also highlights new potential molecular viral targets. These include the down-regulated expression of an extensive list of genes (all centrosome-related) previously associated with autosomal recessive primary microcephaly (ASPM, CENPF, MCPH1, STIL, Cep135). 60, 61 This suggests that the underlying pathogenesis of autosomal recessive and virally induced microcephalies may be similar, although this is yet to be confirmed. [63] [64] [65] [66] [67] [68] Prevalence of congenital CMV infection in high-income countries is estimated to be 0·7% of all live births, or 1-5% in low-income countries. 63, 66, 69 The risk of in utero transmission varies according to whether maternal CMV infection is primary, a reactivation of latent infection, or superinfection with another CMV strain. 63 Primary infection has the highest risk of in-utero transmission and fetal disease is more severe, particularly when it occurs earlier in pregnancy. Overall, most cases of congenital CMV infection result from nonprimary maternal infection but most of these are asymptomatic. 70 The risk of transmission increases with advancing gestational age, with 35% of mothers who have a primary infection in the first trimester giving birth to infected newborns, compared to 65% who are infected in the third trimester. 71 Rates of transmission in non-primary infection are less certain but are generally reported to be lower. 63, 72, 73 The risk of congenital CMV infection is increased by maternal HIV infection both for HIV exposed uninfected and HIV infected infants. 63 In-utero HIV transmission has been shown to be particularly associated with congenital CMV. 74 
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HSV
Primary microcephaly is a relatively rare complication of perinatal HSV infection and is mainly found in association with in-utero infection which accounts for only 5% of cases. 75 Global average seroprevalence is 18% amongst women of childbearing age but this includes huge variations: from 4·1% in Japan to 62% in East Asia and 70% in Sub-Saharan Africa. 76, 77 Neonatal infection at the time of birth from mothers with symptomatic genital infection is more common but does not cause primary microcephaly.
Rubella
Rubella is a vaccine-preventable disease and rates of infection are largely dependent on the coverage of immunisation programmes. The global incidence of congenital rubella syndrome has reduced from 0·1-0·2 per 1000 live births prior to vaccination to near elimination (<0·01 per 100,000 live births) in areas with comprehensive vaccination rates. 78 Vaccination programmes were widespread in most countries in 2014 except in Sub-Saharan Africa and South Asia.
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Despite widespread vaccination programmes an estimated 9.4% of pregnant women remain seronegative worldwide and therefore susceptible to infection. 80 In areas without vaccination programmes, incidence of congenital rubella syndrome has been estimated at 19-283 per 100,000
live births in the African region and 18-309 per 100,000 live births in the South Asian region.
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T. gondii
Most women of childbearing age in Latin America (51-72%), Central Europe (58%), and West Africa (54-77%) have specific IgG antibodies to T. gondii. 81 Conversely, relatively few women of childbearing age are found to be seropositive in South-east Asia, China and Korea (4-39%), Scandinavia (11-28%), and the United States (15%). 81, 82 Mother-to-child transmission predominantly occurs following primary infection during pregnancy. The global incidence of congenital toxoplasmosis is estimated at 1·5 cases per 1000 live births (95% credible interval 1·4, 1·6), being highest in some Latin America countries (average, 3·4 per 1000) and lowest in parts of Europe (0·5 per 1000). 83 The risk of congenital infection may rise due to reactivation of T.
gondii from immunosuppression, for example resulting from HIV. with ZIKV. 87 The prevalence of suspected disease in women of childbearing age is 5400 per 100,000 in Brazil.
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Laboratory diagnosis during pregnancy
Any pregnant woman presenting with fever and/or rash should be evaluated for risk of infections that are potentially transmitted to the fetus. There are many infectious causes of rash, for example Parvovirus B19, measles and varicella zoster, and extensive guidelines exist describing when testing should be done. 89 During the acute infection, laboratory confirmation is usually only possible where clinical symptoms are present in the mother. Primary CMV, HSV, T. gondii, and ZIKV infections may be asymptomatic and therefore the opportunity to confirm acute infection can be missed. 90 In acute symptomatic maternal infection, ZIKV and rubella can be detected in serum, blood, oral fluid or urine by PCR amplification of nucleic acid and may precede the development of IgM antibodies. 95 High levels of IgG antibodies may also be present during the acute phase of infection. 96 In general, detection of CMV IgM, has been shown to lack sensitivity and specificity, especially in conditions of immune dysfunction. A positive CMV IgM is associated with primary infection in only 10% of cases. To distinguish between acute and chronic infections, ELISA-based IgG avidity tests are widely recommended: low-avidity antibodies are typically found over the first weeks, while high-avidity IgG predominates in the chronic phase. 93 IgM and IgG antibody tests for dengue, West Nile fever and ZIKV members of the flaviviridae family share considerable epitope cross-reactivity. Plaque reduction neutralising tests can be used to differentiate closely related viruses but is too complex for routine diagnosis especially in nonspecialised laboratories.
In-utero testing
In the event that acute maternal infection with any of the above pathogens is considered to pose a risk, infection of the infant can be investigated where possible by amplification of pathogen nucleic acid from amniotic fluid. Amniotic fluid samples are typically obtained at 18 weeks gestation to determine fetal infection with T. gondii and guide therapy. 97 In CMV infection, there is a 6-8 week window between maternal infection and being able to detect the virus in amniotic fluid. PCR has high sensitivity when performed at the correct time (20-21 weeks gestation or 7
weeks after maternal infection) and, when combined with culture, nearly all congenital infection can be diagnosed. 63 PCR testing of amniotic fluid for HSV is possible but does not seem to correlate with neonatal infection, 98 and has recently been shown to be possible with ZIKV. now rarely seen after the current approach of systematic prenatal screening and treatment was implemented in France. 101 Screening for CMV in some high-income countries and for ZIKV in countries with high levels of transmission are being considered however, it is not currently recommended for either.
Clinical presentation at birth
Whilst infection can cause both primary and secondary microcephaly, the main focus of this review is the effect of congenital infections on neurogenesis or antenatal neural progenitor death usually associated with primary microcephaly, i.e. it is present at birth. Evaluation of an infant with suspected microcephaly at birth seeks to meet three goals: (1) confirm the diagnosis of microcephaly; (2) identify the cause and attempt syndromic diagnosis; and (3) aid prognosis and guide initial treatment where appropriate. Figure 3 
Measurement of the OFC (illustrated in
Identifying Specific Infectious Causes
Common clinical features for each infection are shown in the appendix and a summary of diagnosis and treatment recommendations are given in 
Rubella
Fetal abnormalities resulting from in utero transmission of rubella range in severity according to the gestation at the time of infection. Infection in the first trimester is associated with more severe abnormalities. 106 Symptomatic infection in the infant is referred to as congenital rubella syndrome (CRS) with a classic triad of cataracts, sensorineural deafness and cardiac defect (e.g. patent ductus arteriosus, ventricular septal defect). 107 Estimates of the frequency of microcephaly in CRS vary but have been reported to be as high as a third of cases overall.
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T. gondii
Approximately 24% of live born infants infected with T. gondii are symptomatic at birth. 109 The 10,000 infected women in first trimester in French Polynesia. 112 Congenital disease has predominantly been seen in Brazil, but this may spread across Latin America. Brasil et al followed up ZIKV affected pregnant women in Rio de Janeiro and found that 3.4% had microcephaly and 42% had abnormal clinical or radiological findings in the first month, mostly affecting the central nervous system. 113 The spectrum of congenital Zika syndrome (CZS) includes birth defects associated with microcephaly (including hearing loss and ophthalmological defects) and how they are related to timing of infection, and presence or absence of maternal symptoms, as well as the influence of other arboviral infections has yet to be fully delineated.
Currently, most of what is known about CZS comes from neonates with microcephaly which appears to include syndrome-specific features such as partially collapsed skull, reduced cortical thickness and extensive subcortical calcifications. 114, 115 However, the full spectrum will only become clear when cohorts of infected mothers provide in-depth report of the clinical presentation. Brain damage or ocular lesions can be found in the absence of microcephaly and other features, as described in the appendix, are common. 14, 116, 117 It is yet to be shown whether there is ongoing viral replication at the time of birth in congenital ZIKV infection. This will have important implications for the potential efficacy of postnatally administered antiviral therapy.
Markers for Prognosis
Microcephaly outcomes are varied, and more accurate prognosis at the time of diagnosis is one of the main aims of clinical evaluation of the neonate. Neuroimaging-for example crUS, CT and MRI-has proven a useful predictive investigation and is warranted in neonates with severe microcephaly, or where a congenital infection is suspected. 118 Whilst different modalities have specific advantages (e.g. good visibility of calcifications on CT, bedside availability of crUS), many structural abnormalities caused by disruptions in development can be identified across modalities. Typical abnormalities include intracranial calcifications, white matter abnormalities (e.g. periventricular leukomalacia, delayed myelination; best seen on MRI), gyration defects (e.g. polymicrogyria), and schizencephaly.
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Long-term consequences and resulting disability in childhood
Long-term follow-up is recommended for infants with microcephaly and even for those with congenital infections and who are apparently unaffected at birth in order to manage evolving conditions and identify new manifestations early. In many cases, the cause of microcephaly will not be known and generic plans can be adopted to manage impairments and limit disability. The timing of the interventions vary in importance. Hearing screening for example needs to be done early to enable interventions to optimise language development. Other interventions, including psychosocial support and counselling, 120 are required throughout childhood and into adult life.
Where microcephaly occurs, recommendations are for early intervention to address associated impairments, calling upon a host of specialist medical and educational services. 121 Currently, regular follow-up is recommended for ZIKV associated microcephaly for anthropometry, developmental and neurological assessments and also hearing and ophthalmological assessment where required over the first two years, with less frequent follow-up recommended for infants without microcephaly. 1 Evidence-based therapy strategies exist that may improve cognitive outcomes and reduce disability. 122 Interventions in early life, for example child stimulation, 123 maximise the plasticity of the developing brain, attenuating the consequences of the damage to the nervous system. But such recommendations ignore the realities of life in many countries.
Issues begin at birth, for example, in some societies, children with visible disabilities are allowed to die in the neonatal period, either through active infanticide or through withdrawal of basic care such as feeding.
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The provision of both recommended early diagnosis, and appropriate interventions may be severely limited in countries with only a handful of specialists, where early intervention programmes or inclusive education efforts remain rare and are largely urban-based. Based on a small but growing literature on disability, individuals with more severe disabilities are far less likely to receive appropriate medical care, attend school or are included in the social, economic or religious life of their communities. 125 This is compounded in poorer households, which often choose to invest limited resources on non-disabled children, whom they feel will be able to contribute to the household in future. 126 Although social protection schemes are beginning in many middle-income countries, 129 the cost of raising and supporting a disabled child continues to be borne almost entirely by the immediate family. Households with disabled members are on average, poorer because of increased costs and because family members, in particular women, must take time away from income generating activities to provide care. 130 Improved services and support for affected individuals and families across the lifespan must be anticipated, and health professionals must work with civil society organisations, including disabled peoples organisations, to ensure these children and their families receive the medical, educational and social service support they need and are entitled to.
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Conclusions
We have summarised the epidemiology, clinical presentation and the current understanding of the pathogenesis of the major congenital infections associated with microcephaly. Potential inconsistencies in the criteria used to diagnose microcephaly have been highlighted as well as limitations of current diagnostic methods in confirming an infectious aetiology. If microcephaly, as strictly defined by head circumference, is used as a screening tool, it will miss affected infants who do not manifest with a small head size. Many infants are likely to have subtle deficits needing more sensitive neurological and developmental assessments. Microcephaly is also usually only one manifestation in a syndrome and other assessments are required to identify the full spectrum of illness.
ZIKV has brought the attention of the world to the problem of microcephaly. The extent of the disease burden resulting from ZIKV is still being clarified but it appears to be significant and is one of a number of infections associated with primary microcephaly. On an individual level, accurate diagnosis and thorough investigation of confirmed microcephaly can guide management and determine prognosis. On a population level, assessing the overall burden and contribution of different causes will guide future interventions and strategies for prevention. Preventing infection, where possible, must be prioritized. It is not within the scope of this review to fully consider health protection and primary prevention but key interventions exist, for example population immunisation for rubella and vector control for ZIKV. Pharmacological interventions are able to treat some congenital infections and therefore limit further damage to the child's developing nervous system (CMV, HSV, T.gondii). Antiviral treatments are not currently available to treat ZIKV in pregnancy but vaccines are in development. Interventions to attenuate the effects of the developmental delay, and at the community or population level to minimize impairment caused by infections that can lead to microcephaly are all needed. More clinical and health system research is crucial to provide scalable interventions to reduce the disability associated with microcephaly. Many interventions designed to optimise neurodevelopmental outcomes in infected infants will be common to all congenital infections and enhanced services for ZIKV follow up could potentially also be used in the future for the benefit of children severely affected by other congenital infections.
Regions in which the infective burden is highest are also likely to be those where diagnosis and management is most lacking, creating a disproportionately large burden on populations that can least afford it. Inequities in access to optimised multidisciplinary care for children with neurodisability in areas with the highest rates of microcephaly means that the prognosis for those infants is often very poor. ZIKV has highlighted the issue of microcephaly and provides a timely opportunity to refocus on the whole group of infectious diseases which can affect the developing fetal brain and to redouble our efforts for prevention and treatment in the short-and long-term for those living with the frequently devastating consequences of such congenital infections. Simulated populations were created using R language and environment for statistical computing.
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If an otherwise normal population of 1000 infants (in which children's occipito-frontal circumferences (OFCs) are close to their expected values) is exposed to a congenital infection that limits brain development, a proportion of children are labelled as "normal" by being above the -2 z-scores (standard deviations (SD)) or -3 z-scores cut-offs but they may deviate from their "expected" OFC.
Scenario 1 describes a congenital infection with a uniform shift to the left by 1 SD relative to the reference curve in 30% (randomly chosen) of affected children, roughly as expected in congenital toxoplasmosis acquired late in pregnancy. The remaining 70% children were not affected at all.
In this hypothetical scenario, 6·5% of children fall below -2 z-score cut-off value for microcephaly; 0·9% below the -3 z-scores. Only 65 of the 300 (21·7%) of the "affected" children will actually be classified as "microcephalic" by using the -2 z-score cut-off. Only children whose "ideal" OFC would be less than -1 SD of the expected mean (expected proportion of 15·9% in a healthy population), would actually be diagnosed as "microcephalic" after the 1 SD shift caused by the infection.
Scenario 2 is a congenital infection where OFC is shifted to the left by 2 SD in 10% of children, roughly as expected for congenital toxoplasmosis acquired early in pregnancy. In this hypothetical scenario, 6·5% of children fall below -2 z-score cut-off value for microcephaly; 1·4% below the -3 z-scores. Here, 65% of "affected" children will fall below the cut-off value of -2 SD.
By counting the number of children below a given cut-off value we are severely underestimating not only the proportion of children who have been relatively mildly affected (Scenario 1) but also that of children who have been more severely affected (Scenario 2). Moreover, although Scenarios 1 and 2 represent conditions varying in severity which affect different proportions of children in the population, in both examples the prevalence of microcephaly, estimated by applying the -2 z-score cut-off, would be quite similar (around 6.5%). 
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